Clinical Trials Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.

Total 1146 results

Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Advanced Solid Tumor

Australia, China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-02 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Australia, China, United States
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

China, Australia
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Neoplasms | Neoplasm Metastasis | Metastatic Gastrointestinal Carcinoid Tumor

United States, China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Neovascular Age-Related Macular Degeneration

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration

China
Innostellar Biotherapeutics Co.,Ltd

Active, not recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Inherited Retinal Dystrophy Associated With RPE65 Mutations

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)

Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Unknown

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Solid Tumor | CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
InventisBio Co., Ltd
InxMed (Shanghai) Co., Ltd.

Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Solid Tumor

China
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai HyaMab Biotech Co.,Ltd.

Not yet recruiting

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Advanced Solid Tumors
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Healthy

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Advanced Solid Tumors

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Small Cell Lung Cancer Extensive Stage

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Shanghai GeneChem Co., Ltd.

Unknown

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Leukemia, B-Cell

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets for APDS/PASLI

PI3K and P110delta Hyperactivation Syndrome

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma

United States, Australia
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
Hepagene (Shanghai) Co., Ltd.

Active, not recruiting

Phase 2a Study of HPG1860 in Subjects With NASH (RISE)

NASH - Nonalcoholic Steatohepatitis

United States
Shanghai Cingularbio Co. Ltd

Completed

Cingularbio® Heart Valve Clincial Study

Diseases of Mitral and Aortic Valves

China, Belgium, Poland
Hepagene (Shanghai) Co., Ltd.

Completed

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

Healthy

United States
Shanghai GeneChem Co., Ltd.

Unknown

A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (GPC3-CART)

Carcinoma, Hepatocellular

China
InxMed (Shanghai) Co., Ltd.

Not yet recruiting

IN10018 Combination Therapy in Previously-treated Solid Tumors

Solid Tumor
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
Shanghai GeneChem Co., Ltd.

Unknown

A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (meso-CART)

Pancreatic Cancer

China
Tongji Hospital
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System (CARTinNS)

Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Immune-Mediated Necrotizing Myopathy

China
Changhai Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Not yet recruiting

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Digestive Tumor
Shanghai NewMed Medical Co., Ltd.
Shanghai Phigine Medical Technology Co., Ltd.

Not yet recruiting

Phitys I™ Percutaneous Left Ventricular Assist System Study

Coronary Artery Disease

China
Oneness Biotech Co., Ltd.
Microbio Shanghai Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

Allergic Asthma

Taiwan
Wuhan BravoVax Co., Ltd.
Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Herpes Zoster

Clinical Trials Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations